Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis [0.03%]
IL-12/23和IL-23抑制剂诱导及维持治疗中重度克罗恩病疗效的系统评价和网络 meta 分析
Mohammad Al Hayek,Bisher Sawaf,Mohammed S Beshr et al.
Mohammad Al Hayek et al.
Introduction: Interleukin (IL)-12/23 and IL-23 inhibitors have emerged as promising therapeutic options for moderate-to-severe Crohn's disease (CD), but comparative data between agents remain limited. This study aimed to ...
The Impact of Mesalazine Pill Burden on Compliance in Inflammatory Bowel Disease Patients [0.03%]
美沙拉嗪片剂负荷量对炎症性肠病患者依从性的影响
Julien Kirchgesner,Helen Thorne,Ekaterina Safroneeva et al.
Julien Kirchgesner et al.
Introduction: There are a limited number of studies that have investigated mesalazine persistence and adherence using administrative/pharmacy claims data that may approximate real-world clinical practice data; therefore, ...
Histological Predictors for Therapeutic Response to Integrin Inhibitors in Patients with Ulcerative Colitis [0.03%]
溃疡性结肠炎患者的整合素抑制剂治疗反应的组织病理学预测因素
Takuya Kimizuka,Atsushi Yoshida,Fumiaki Ueno et al.
Takuya Kimizuka et al.
Introduction: It is crucial to predict the effectiveness of advanced therapies before their administration in ulcerative colitis (UC). Only a few studies have revealed predictive histological factors. Here, we sought to d...
Mucosal Healing of Ulcerative Colitis Based on Endoscopic Diagnosis, Histopathology, and Mucosal Inflammatory Mediators [0.03%]
基于内镜诊断、组织病理学和黏膜炎症介质的溃疡性结肠炎黏膜愈合研究
Kazuhiko Uchiyama,Tomohisa Takagi,Eiki Murakami et al.
Kazuhiko Uchiyama et al.
Background: Mucosal healing is necessary to maintain the long-term remission of ulcerative colitis (UC). Currently, the gold standard for assessing mucosal healing is endoscopic diagnosis. The Mayo Endoscopic Subscore (ME...
Real-World Data on the Effectiveness of Ustekinumab and Risankizumab for Crohn's Disease [0.03%]
关于乌司奴单抗和里萨珠单抗治疗克罗恩病有效性的真实世界数据研究
Ryo Morikawa,Toshimitsu Fujii,Akiko Tamura et al.
Ryo Morikawa et al.
Introduction: No real-world studies have compared efficacy of ustekinumab (UST) and risankizumab (RZB) for the treatment of Crohn's disease (CD). Methods:...
Pregnancy and Preconception Care for Patients with Inflammatory Bowel Disease [0.03%]
炎症性肠病患者的妊娠与孕前护理
Namiko Hoshi,Yuna Ku,Makoto Ooi
Namiko Hoshi
Background: For both men and women, family planning, including decisions regarding marriage and childbearing, is a significant life event that contributes to overall "happy life." Patients with chronic diseases such as in...
Survey of Patient Satisfaction and Willingness to Pay for Shared Decision-Making Implemented by Pharmacists for Patients with Inflammatory Bowel Disease [0.03%]
炎症性肠病患者对药师实施的共同决策的满意度及支付意愿调查研究
Momoko Konaka,Ikkou Hirata,Hiroki Oba et al.
Momoko Konaka et al.
Introduction: Biologics and Janus kinase inhibitors have emerged as treatment options for inflammatory bowel disease (IBD); however, Japanese guidelines do not specify priorities for the use of these therapies. Therefore,...
Junji Umeno,Motohiro Esaki,Keiichi Uchida et al.
Junji Umeno et al.
Background: Chronic enteropathy associated with SLCO2A1 gene (CEAS) is a rare hereditary disorder characterized by multiple small intestinal ulcers, chronic anemia, and hypoproteinemia. Initially reported by Okabe et al. ...
Christoph Schlag
Christoph Schlag
Background: Eosinophilic esophagitis (EoE) is a chronic inflammatory immune-mediated disease characterized by eosinophilic esophageal inflammation, leading to remodeling, fibrosis, and stricture formation. Esophageal dila...
Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative Analysis [0.03%]
Janus激酶抑制剂治疗溃疡性结肠炎患者（≥65岁和
Shintaro Akiyama,Hiromichi Shimizu,Akiko Tamura et al.
Shintaro Akiyama et al.
Introduction: It remains unclear whether Janus kinase (JAK) inhibitors differ in efficacy and safety between elderly and non-elderly patients with ulcerative colitis. ...